

## Data Sharing Statement

<b>Article Info</b>	<a href="https://dx.doi.org/10.21037/jgo-23-167">https://dx.doi.org/10.21037/jgo-23-167</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The survival data in particular will be shared, and we also found that in the process of immunotherapy for HCC patients, the time window for treatment may need to be extended. An analysis of AFP may assist the imRECIST by providing a more accurate evaluation of tumor progression.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date.
7	To whom will you share the data?	Medical oncologists and liver cancer surgeons who are interested in studies of immunotherapy
8	For what type of analysis or purpose?	To study the clinical value of immunotherapy in HCC patients.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: 491378505@qq.com
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.